<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39353741</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5010</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society</Title><ISOAbbreviation>J Cyst Fibros</ISOAbbreviation></Journal><ArticleTitle>Assessing <sup>129</sup>Xe multi-breath washout MRI response to elexacaftor/tezacaftor/ivacaftor intervention in pediatric CF.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1569-1993(24)01789-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcf.2024.09.021</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Monitoring multiple-breath washout (MBW) of a xenon tracer using magnetic resonance imaging (MBW Xe-MRI) provides quantitative regional measures of gas washout (fractional ventilation, FV) and spatial ventilation heterogeneity (coefficient of variation, CoV<sub>FV</sub>) in pediatric CF lung disease, but has yet to be evaluated in an interventional setting.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">12 pediatric CF participants (median age 15.3 ± 2 years) completed MBW Xe-MRI, pulmonary function tests (PFTs) (spirometry, N<sub>2</sub> MBW for lung clearance index (LCI)) and single-breath Xe-MRI ventilation defect percent (VDP) measurements at baseline and 1-month post-initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy. FV maps were calculated from MBW Xe-MRI washout images, and CoV<sub>FV</sub> maps were derived from FV maps. Significant changes between visits were determined using a paired Wilcoxon signed-rank test. For correlations between absolute changes, Pearson's correlation was used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All measures changed significantly 1-month post-ETI therapy compared to baseline. For MRI metrics, median [IQR] VDP was significantly (P &lt; 0.001) lower at 1 month (8.0 [3.7 12.4]) compared to baseline (17.8 [8.3 22.5]), FV was significantly (P &lt; 0.05) higher at 1 month (0.42 [0.41 0.46]) compared to baseline (0.38 [0.33 0.44]), and CoV<sub>FV</sub> was significantly (P &lt; 0.001) lower at 1 month (0.06 [0.05 0.07]) compared to baseline (0.09 [0.08 0.12]). Both absolute and relative differences in CoV<sub>FV</sub> and LCI were found to correlate highly (R = 0.92, P &lt; 0.0001 and R = 0.91, P &lt; 0.0001, respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Functional information derived from MBW Xe-MRI, particularly CoV<sub>FV</sub>, can be used to assess regional lung function in pediatric CF patients in an interventional setting and may be complementary to VDP and pulmonary function tests.</AbstractText><CopyrightInformation>Copyright © 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alam</LastName><ForeName>Faiyza</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada. Electronic address: faiyza.alam@sickkids.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munidasa</LastName><ForeName>Samal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanette</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braganza</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Renee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumas</LastName><ForeName>Marie-Pier</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada; Clinical Epidemiology &amp; Health Care Research, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratjen</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada; Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santyr</LastName><ForeName>Giles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Cyst Fibros</MedlineTA><NlmUniqueID>101128966</NlmUniqueID><ISSNLinking>1569-1993</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fractional ventilation</Keyword><Keyword MajorTopicYN="N">Hyperpolarized (129)Xe</Keyword><Keyword MajorTopicYN="N">Lung clearance index</Keyword><Keyword MajorTopicYN="N">Multiple-breath washout</Keyword><Keyword MajorTopicYN="N">Pediatric</Keyword><Keyword MajorTopicYN="N">elexacaftor/tezacaftor/ivacaftor</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>21</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39353741</ArticleId><ArticleId IdType="doi">10.1016/j.jcf.2024.09.021</ArticleId><ArticleId IdType="pii">S1569-1993(24)01789-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle>